-
公开(公告)号：US20180344835A1
公开(公告)日：2018-12-06
申请号：US15562167
申请日：2016-03-29
Applicant: Boehringer Ingelheim Vetmedica, Inc.
Inventor： Luis Alejandro HERNANDEZ , Eric Martin VAUGHN
IPC: A61K39/12 , C07K14/005 , C12N15/62 , C07K1/14 , G01N33/53 , G01N33/566 , A61P31/20
CPC classification number: A61K39/12 , A61K2039/5258 , A61K2039/552 , A61K2039/6075 , A61P31/20 , C07K1/14 , C07K14/005 , C07K2319/40 , C12N15/62 , C12N2750/10022 , C12N2750/10023 , C12N2750/10034 , C12N2770/10022 , C12N2770/10034 , C12N2799/026 , G01N33/5308 , G01N33/566
Abstract: The present invention relates to an immunogen-carrier, wherein the immunogen-carrier is preferably a virus-like particle (VLP) composed of a plurality of a modified PCV2 ORF2 protein. In particular, the present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a compliance marker for vaccines including a subunit antigen, and a DIVA (Differentiating Infected from Vaccinated Animals) system which makes it possible to differentiate between animals infected with a pathogen and animals treated with a subunit antigen derived from said pathogen.
-
公开(公告)号：US20180289795A1
公开(公告)日：2018-10-11
申请号：US16015512
申请日：2018-06-22
Applicant: Boehringer Ingelheim Vetmedica, Inc.
Inventor： Marc Allan EICHMEYER , Wesley Scott JOHNSON , Eric Martin VAUGHN , Michelle L. WALZ
IPC: A61K39/145 , C12N7/00 , C07K14/005 , A61K39/12 , A61K39/00
Abstract: The present invention relates to an immunogenic composition comprising: a) a modified live H3 virus of swine influenza, and b) a modified live H1 virus of swine influenza. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by swine influenza virus in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
-
公开(公告)号：US20180207260A1
公开(公告)日：2018-07-26
申请号：US15920565
申请日：2018-03-14
Applicant: Boehringer Ingelheim Vetmedica, Inc.
Inventor： Luis Alejandro HERNANDEZ , Arun V. IYER , Dianna M. Murphy JORDAN , Abby Rae PATTERSON , Michael B. ROOF , Eric Martin VAUGHN , Joseph Gilbert VICTORIA
IPC: A61K39/215 , C12N7/00 , C07K14/005 , C07K16/10 , A61K45/06 , A61K39/00
Abstract: The present invention relates to a vaccine for protecting a pig against diseases associated with porcine epidemic diarrhea virus. The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and methods of producing the porcine epidemic diarrhea virus vaccine are also provided.
-
4.发明申请公开(公告)号：US20170029471A1
公开(公告)日：2017-02-02
申请号：US15295053
申请日：2016-10-17
Applicant: Boehringer Ingelheim Vetmedica, Inc.
Inventor： Luis Alejandro HERNANDEZ , Christine Margaret MUEHLENTHALER , Eric Martin VAUGHN , Gregory HAIWICK
IPC: C07K14/005 , A61K39/12 , C12P21/02 , C12N7/00
CPC classification number: C07K14/005 , A61K39/00 , A61K39/12 , A61K2039/5256 , A61K2039/5258 , A61K2039/53 , C12N7/00 , C12N2710/14043 , C12N2750/10022 , C12N2750/10023 , C12N2750/10034 , C12N2750/10051 , C12N2799/026 , C12P21/02
Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.
Abstract translation: 公开了用不同PCV2亚型控制PCV2感染的疫苗接种方法。 具体地说，在用于治疗或预防相同PCV2b和/或不同亚型的PCV2的感染的方法中使用包含PCV2b ORF2蛋白的PCV2亚型b（PCV2b）ORF2蛋白或免疫原性组合物; 减少，预防或治疗由相同PCV2b或不同亚型的PCV2感染引起的临床症状; 和/或预防或治疗由相同PCV2b和/或不同亚型的PCV2感染引起的疾病。 本发明特别涉及PCV2亚型b（PCV2b）ORF2蛋白，其特征在于它们在BC环中含有至少一个突变，使得与不携带的PCV2 ORF2蛋白相比，表达的蛋白优选以更高的量表达 含有这种突变。
-
5.发明申请ORF2 PROTEIN OF PCV2 SUBTYPE A (PCV2A) FOR USE IN CROSS-PROTECTION 审中-公开用于交叉保护的PCV2亚型A（PCV2A）的ORF2蛋白质公开(公告)号：US20160206727A1
公开(公告)日：2016-07-21
申请号：US15088442
申请日：2016-04-01
Applicant: Boehringer Ingelheim Vetmedica, Inc.
Inventor： Gregory HAIWICK , Luis HERNANDEZ , Wesley Scott JOHNSON , Christine Margaret MUEHLENTHALER , Eric Martin VAUGHN
CPC classification number: A61K39/12 , A61K39/0208 , A61K39/0258 , A61K39/04 , A61K39/05 , A61K39/08 , A61K39/085 , A61K39/092 , A61K39/145 , A61K39/215 , A61K39/23 , A61K39/235 , A61K39/245 , A61K2039/545 , A61K2039/552 , A61K2039/55555 , A61K2039/70 , C12N7/00 , C12N2750/10022 , C12N2750/10034
Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype a (PCV2a) ORF2 proteins or immunogenic compositions comprising a PCV2a ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of a different subtype, the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of a different subtype, or the prevention or treatment of a disease caused by an infection with PCV2 of a different subtype.
Abstract translation: 公开了用不同PCV2亚型控制PCV2感染的疫苗接种方法。 具体地说，将PCV2亚型（PCV2a）ORF2蛋白质或包含PCV2a ORF2蛋白质的免疫原性组合物用于治疗或预防不同亚型的PCV2感染的方法，减少，预防或治疗由 不同亚型的PCV2的感染，或预防或治疗由不同亚型的PCV2的感染引起的疾病。
-
Patent Agency Ranking
公开(公告)号：US20150283230A1
公开(公告)日：2015-10-08
申请号：US14721490
申请日：2015-05-26
Applicant: Boehringer Ingelheim Vetmedica, Inc.
Inventor： Arun V. IYER , Dianna M. Murphy JORDAN , Abby Rae PATTERSON , Michael B. ROOF , Eric Martin VAUGHN , Joseph Gilbert VICTORIA , Callie Ann VISEK
IPC: A61K39/23 , C12N7/00 , G01N33/569
CPC classification number: A61K39/23 , A61K2039/53 , C07K14/005 , C12N7/00 , C12N2750/14321 , C12N2750/14322 , C12N2750/14334 , G01N33/56983 , G01N2333/015 , G01N2469/10
Abstract: The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5B (PPV5B) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.
Abstract translation: 本发明提供新颖的核苷酸序列，蛋白质序列，免疫原性组合物，疫苗和涉及制造和使用感染尤其是家猪的新型猪细小病毒5B（PPV5B）的方法。 组合物和方法提供了用于检测所述新病毒的感染，监测野生和家畜和猪群中的病毒序列的遗传变化，以及制备和使用新型疫苗以保护动物免受病毒感染。
-
公开(公告)号：US20150283229A1
公开(公告)日：2015-10-08
申请号：US14672631
申请日：2015-03-30
Applicant: Boehringer Ingelheim Vetmedica, Inc.
Inventor： Luis Alejandro HERNANDEZ , Arun V. IYER , Dianna M. Murphy JORDAN , Abby Rae PATTERSON , Michael B. ROOF , Eric Martin VAUGHN , Joseph Gilbert VICTORIA
IPC: A61K39/215 , C12N7/00 , A61K45/06
CPC classification number: A61K39/215 , A61K45/06 , A61K2039/5252 , A61K2039/552 , C07K14/005 , C07K16/10 , C07K2317/76 , C12N7/00 , C12N2710/14043 , C12N2710/14143 , C12N2770/20021 , C12N2770/20022 , C12N2770/20034 , C12N2770/20063
Abstract: The present invention relates to a vaccine for protecting a pig against diseases associated with porcine epidemic diarrhea virus. The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and methods of producing the porcine epidemic diarrhea virus vaccine are also provided.
Abstract translation: 本发明涉及一种用于保护猪免受猪流行性腹泻病毒相关疾病的疫苗。 疫苗通常包括灭活/杀死的PEDV（例如化学灭活的PED病毒）和/或重组PEDV抗原和佐剂。 还提供了保护猪免受PEDV相关疾病的方法以及生产猪流行性腹泻病毒疫苗的方法。
-
公开(公告)号：US20150246113A1
公开(公告)日：2015-09-03
申请号：US14713700
申请日：2015-05-15
Applicant: Boehringer Ingelheim Vetmedica, Inc.
Inventor： Arun V. IYER , Dianna M. Murphy JORDAN , Abby Rae PATTERSON , Michael B. ROOF , Eric Martin VAUGHN , Joseph Gilbert VICTORIA , Callie Ann VISEK
CPC classification number: A61K39/23 , A61K2039/5252 , A61K2039/5254 , A61K2039/552 , C07K14/005 , C12N7/00 , C12N2750/14021 , C12N2750/14022 , C12N2750/14034 , G01N33/6893
Abstract: The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5A (PPV5A) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.
Abstract translation: 本发明提供新颖的核苷酸序列，蛋白质序列，免疫原性组合物，疫苗以及涉及制造和使用感染尤其是家猪的新型猪细小病毒5A（PPV5A）的方法。 组合物和方法提供了用于检测所述新病毒的感染，监测野生和家畜和猪群中的病毒序列的遗传变化，以及制备和使用新型疫苗以保护动物免受病毒感染。
-
9.发明申请公开(公告)号：US20160258953A1
公开(公告)日：2016-09-08
申请号：US15061690
申请日：2016-03-04
Applicant: Boehringer Ingelheim Vetmedica, Inc.
Inventor： Arun V. IYER , Joseph Ralph HERMANN , Michael B. ROOF , Eric Martin VAUGHN , Merrill Lynn SCHAEFFER
IPC: G01N33/569 , C12N7/00 , C12P21/00 , A61K39/145 , C12Q1/70 , G01N33/68 , C07K14/005 , A61K39/12
CPC classification number: G01N33/56983 , A61K39/12 , A61K39/145 , A61K2039/5252 , C07K14/005 , C07K2319/21 , C07K2319/50 , C12N7/00 , C12N2710/14021 , C12N2710/14022 , C12N2710/14043 , C12N2710/14051 , C12N2710/14143 , C12N2750/10034 , C12N2750/10051 , C12N2760/16134 , C12N2760/16151 , C12N2760/20022 , C12N2760/20034 , C12N2760/20051 , C12P21/00 , C12Q1/701 , G01N33/5091 , G01N33/6854 , G01N2333/01
Abstract: The present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a method of determining whether an individual has received an immunogenic composition comprising a recombinant protein produced by a baculovirus expression system in cultured insect cells.
Abstract translation: 本发明属于适应性标记和标记疫苗领域，其允许感染和接种个体之间的分化。 特别地，本发明涉及一种确定个体是否已经接受了包含由培养的昆虫细胞中的杆状病毒表达系统产生的重组蛋白质的免疫原性组合物的方法。
-
公开(公告)号：US20170232094A1
公开(公告)日：2017-08-17
申请号：US15499138
申请日：2017-04-27
Applicant: Boehringer Ingelheim Vetmedica, Inc.
Inventor： Gregory HAIWICK , Marc Allan EICHMEYER , Luis Alejandro HERNANDEZ , Wesley Scott JOHNSON , Christine Margaret MUEHLENTHALER , Eric Martin VAUGHN
CPC classification number: A61K39/12 , A61K2039/5252 , A61K2039/5256 , A61K2039/55 , A61K2039/552 , A61K2039/55516 , A61K2039/55566 , A61K2039/58 , C12N7/00 , C12N2710/14043 , C12N2750/10034
Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of a different subtype, the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of a different subtype, or the prevention or treatment of a disease caused by an infection with PCV2 of a different subtype.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.018 seconds)
